Revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sangamo Therapeutics, Inc (SGMOQ)
Price$0.1611Cached quote
Net income
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $39.6M | $57.8M | $176.2M | $111.3M | $110.7M | $118.2M | $102.4M | $84.5M | $36.6M | $19.4M | $39.5M | $45.9M | $24.1M | $21.7M | $10.3M | $20.8M | $22.2M |
| Research & development | $112.7M | $111.5M | $234.1M | $249.9M | $230.8M | $180.6M | $145.9M | $114.9M | $65.7M | $65.6M | $67.2M | $57.0M | $37.0M | $31.7M | $32.1M | $33.2M | $29.0M |
| Operating expenses | $160.8M | $161.8M | $450.2M | $312.6M | $294.0M | $247.7M | $207.6M | $161.6M | $92.9M | $91.9M | $86.4M | $72.7M | $50.8M | $43.9M | $46.1M | $45.7M | $41.6M |
| Operating income | −$121.2M | −$104.0M | −$274.0M | −$201.3M | −$183.3M | −$129.6M | −$105.2M | −$77.2M | −$56.4M | −$72.6M | −$46.9M | −$26.8M | −$26.7M | −$22.2M | −$35.8M | −$24.9M | −$19.4M |
| Operating margin | −306.53% | −179.88% | −155.48% | −180.85% | −165.61% | −109.61% | −102.69% | −91.35% | −154.13% | −374.23% | −118.51% | −58.38% | −110.66% | −102.51% | −347.14% | −119.85% | −87.45% |
| EBITDA | −$117.3M | −$98.9M | −$258.9M | −$189.2M | −$173.9M | −$123.9M | −$101.3M | −$74.8M | −$54.9M | −$71.6M | −$45.9M | −$26.2M | −$26.1M | −$21.5M | −$35.2M | −$24.3M | −$18.8M |
| EBITDA margin | −296.52% | −171.04% | −146.93% | −169.97% | −157.09% | −104.80% | −98.85% | −88.56% | −150.03% | −369.09% | −116.01% | −57.19% | −108.30% | −99.46% | −340.88% | −116.60% | −84.87% |
| Net income | −$122.9M | −$97.9M | −$257.8M | −$192.3M | −$178.3M | −$121.0M | −$95.2M | −$68.3M | −$54.6M | −$71.7M | −$40.7M | −$26.4M | −$26.6M | −$22.3M | −$35.8M | −$24.9M | −$18.6M |
| Net profit margin | −310.81% | −169.45% | −146.30% | −172.76% | −161.05% | −102.37% | −92.93% | −80.91% | −149.23% | −369.58% | −102.94% | −57.59% | −110.32% | −102.81% | −346.45% | −119.46% | −83.77% |
| Basic EPSper basic share | -$0.44 | -$0.49 | -$1.48 | -$1.25 | -$1.23 | -$0.90 | -$0.85 | -$0.70 | -$0.70 | -$1.02 | -$0.58 | -$0.39 | -$0.48 | -$0.42 | -$0.53 | -$0.41 | -$0.33 |
| Diluted EPSper diluted share | -$0.44 | -$0.49 | -$1.48 | -$1.25 | -$1.23 | -$0.90 | -$0.85 | -$0.70 | -$0.70 | -$1.02 | -$0.58 | -$0.39 | -$0.48 | -$0.42 | -$0.53 | -$0.41 | -$0.33 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Macrae Sandy | 1.9M |
Duraibabu Prathyusha | 660.04K |
Willoughby Scott B. | 647.37K |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 400K |
Dubois-Stringfellow Nathalie | 328.73K |
Jain Nikunj | 235.29K |
Pooler Amy | 193.92K |
Davis Gregory D | 113.65K |
PARKER H STEWART | 112.6K |
Smith Karen L. | 102.1K |
Meyers James R | 99.6K |
Hillan Kenneth J. | 99.6K |
Carey Robert | 99.6K |
Markels John | 96.38K |
Horn Margaret A | 82.65K |
Beers Courtney | 82.65K |
SIMPLEX TRADING, LLC | 76.5K |
Axiom Investment Management LLC | 25.38K |
FLOW TRADERS U.S. LLC | 21.53K |
Heritage Investment Group, Inc. | 10K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 22, 2026Form 4 | Davis Gregory DHead of Research & Technology | SellCommon Stock | 69.8K | $0.25 | $17.5K | 115.3K |
| Apr 21, 2026Form 4 | Dubois-Stringfellow NathalieSVP-CHIEF DEVELOPMENT OFFICER | SellCommon Stock | 345.9K | $0.26 | $89.9K | 332.8K |